Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation
Open Access
- 27 March 2000
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 25 (7) , 765-769
- https://doi.org/10.1038/sj.bmt.1702227
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experienceBone Marrow Transplantation, 1998
- Time course analysis of semi-quantitative PCR and antigenaemia assay for prevention of cytomegalovirus disease after bone marrow transplantationBritish Journal of Haematology, 1998
- Real time quantitative PCR.Genome Research, 1996
- HCMV pp65 antigenemia assay using indirect alkaline phosphatase staining method Biomedical Research, 1995
- Ganciclovir Prophylaxis of Cytomegalovirus Infection and Disease in Allogeneic Bone Marrow Transplant Recipients: Results of a Placebo-Controlled, Double-Blind TrialAnnals of Internal Medicine, 1993
- Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow TransplantAnnals of Internal Medicine, 1993
- Early Treatment with Ganciclovir to Prevent Cytomegalovirus Disease after Allogeneic Bone Marrow TransplantationNew England Journal of Medicine, 1991
- A Randomized, Controlled Trial of Prophylactic Ganciclovir for Cytomegalovirus Pulmonary Infection in Recipients of Allogeneic Bone Marrow TransplantsNew England Journal of Medicine, 1991
- Treatment of Cytomegalovirus Pneumonia with Ganciclovir and Intravenous Cytomegalovirus Immunoglobulin in Patients with Bone Marrow TransplantsAnnals of Internal Medicine, 1988
- Risk Factors for Cytomegalovirus Infection after Human Marrow TransplantationThe Journal of Infectious Diseases, 1986